REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
To determine whether adding panitumumab, an antibody against the epidermal growth factor
receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine
(EOX), improves the duration of survival of patients with advanced stomach and oesophageal
cancer.